<p>Animals received m-HemaMax subcutaneously at a dose of 10 ng/mouse, 20 ng/mouse, 40 ng/mouse, or 200 ng/mouse in the absence of irradiation or at 24 hours after an LD<sub>90/30</sub> of TBI. The plasma concentrations of m-HemaMax were determined by ELISA.</p><p>AUC = area under the curve; C<sub>max</sub> = maximum plasma concentrations; NR = no irradiation; R = irradiation; TBI = total body irradiation; T<sub>max</sub> = time to achieve the maximum plasma concentration; t<sub>1/2</sub> = half life.</p
<p>Body weights in Kg (a and b) and in percentage (c and d) are shown for the 100 ng/Kg and 250 ng/K...
<p>(<b>A</b>) Median RBC core diameter as a function of time for mice receiving heparin infusion (gr...
<p>Mice were injected with PLX-RAD on day 1 and 5 following 7.7 Gy irradiation. The mice were bled a...
<p>Animals received m-HemaMax subcutaneously at a dose of (a) 10 ng/mouse, (b) 20 ng/mouse, (c) 40 n...
<p>(a) Animals received vehicle or m-HemaMax at an ostensible dose of 100 ng/mouse at 24 hours and 7...
<p>Animals received HemaMax subcutaneously at a dose of either 250 ng/Kg or 1000 ng/Kg in the absenc...
<p>The plot of plasma AUC<sub>last</sub> of m-HemaMax versus the dose administered to mice in the ab...
HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medica...
<p>Animals were subjected to an LD<sub>50/30</sub> of TBI at day 0. Animals received subcutaneously ...
<p>(a) Temporal kinetics of IFN-γ relative to that of HemaMax. (b) Temporal kinetics of IL-18 and EP...
HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medica...
<p>IVM or MOX was administered to Mdr1ab(−/−) mice (6 per dose rate) or to wild-type mice (3 per dos...
<p>The IL-12Rβ2 expression in jejunal crypts (a) and the suppression of jejunal expression of LGR5 (...
<p>PK profiles of HC-070 after intravenous (A) and oral (B) administration in C57BL/6 mice. Plasma c...
<p>Individual dosing groups (a) and the pooled HemaMax dosing group (b) are shown. Animals were subj...
<p>Body weights in Kg (a and b) and in percentage (c and d) are shown for the 100 ng/Kg and 250 ng/K...
<p>(<b>A</b>) Median RBC core diameter as a function of time for mice receiving heparin infusion (gr...
<p>Mice were injected with PLX-RAD on day 1 and 5 following 7.7 Gy irradiation. The mice were bled a...
<p>Animals received m-HemaMax subcutaneously at a dose of (a) 10 ng/mouse, (b) 20 ng/mouse, (c) 40 n...
<p>(a) Animals received vehicle or m-HemaMax at an ostensible dose of 100 ng/mouse at 24 hours and 7...
<p>Animals received HemaMax subcutaneously at a dose of either 250 ng/Kg or 1000 ng/Kg in the absenc...
<p>The plot of plasma AUC<sub>last</sub> of m-HemaMax versus the dose administered to mice in the ab...
HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medica...
<p>Animals were subjected to an LD<sub>50/30</sub> of TBI at day 0. Animals received subcutaneously ...
<p>(a) Temporal kinetics of IFN-γ relative to that of HemaMax. (b) Temporal kinetics of IL-18 and EP...
HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medica...
<p>IVM or MOX was administered to Mdr1ab(−/−) mice (6 per dose rate) or to wild-type mice (3 per dos...
<p>The IL-12Rβ2 expression in jejunal crypts (a) and the suppression of jejunal expression of LGR5 (...
<p>PK profiles of HC-070 after intravenous (A) and oral (B) administration in C57BL/6 mice. Plasma c...
<p>Individual dosing groups (a) and the pooled HemaMax dosing group (b) are shown. Animals were subj...
<p>Body weights in Kg (a and b) and in percentage (c and d) are shown for the 100 ng/Kg and 250 ng/K...
<p>(<b>A</b>) Median RBC core diameter as a function of time for mice receiving heparin infusion (gr...
<p>Mice were injected with PLX-RAD on day 1 and 5 following 7.7 Gy irradiation. The mice were bled a...